Leerink Partners 2025 Global Healthcare Conference Call March 12, 2025 11:20 AM ETCompany ParticipantsRoland Chen ...

BMY is banking on new drugs to offset generic competition for older drugs. However, this might not be enough as the outlook ...

For around 70 years, the treatment of schizophrenia has relied almost entirely on drugs that block dopamine receptors, so Cobenfy's action on cholinergic receptors offers a brand new way to treat ...

Bristol Myers Squibb and Alexandria Real Estate are top picks for the income-focused, offering high dividends and growth ...

We recently published a list of Jim Cramer’s Latest Portfolio: Top 10 Stocks to Watch. In this article, we are going to take ...

Bristol Myers BMY announced that the European Commission (EC) has approved the blockbuster immuno-oncology drug Opdivo ...

Cobenfy is a combination of a muscarinic M1 ... It came just a few days after AbbVie agreed a $10.1 billion deal to buy antibody-drug conjugate developer ImmunoGen. CNS is a key therapeutic ...

With Cobenfy now available for adults with schizophrenia, we look forward to further understanding the real-world impact of this differentiated treatment option,” Dr Johnson noted. The US Food and ...

Instead, many investors are tracking the launch of the newly approved antipsychotic Cobenfy, which BMS picked up from its $14 billion acquisition of Karuna Therapeutics last year.